From laboratory to bedside: a case report of a concise and pragmatic approach on heart failure

Andrea Pizzini, Marco Badinella Martini



Heart failure is one of the most common and intensely studied diseases in the world. Nevertheless, it is considered a difficult condition to diagnose and manage.

This case report, starting from the description of a brief clinical case, aims to directly and concisely explain the most important steps, from laboratory to bedside, in the diagnosis and management of heart failure disease. Physicians can rely on some laboratory tests (e.g., natriuretic peptides) and instrumental exams to diagnose and manage the patients in everyday medical practice. Finally, this article highlights that a multidisciplinary team management can improve the clinical status and the quality of life, thus preventing hospital admission and reducing mortality in patients with heart failure.


Heart failure, Natriuretic peptides, Laboratory tests, General practice, Multidisciplinary team management

Full Text



  • McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC (HFA). Eur Heart J 2012; 33: 1787-847;
  • Mosterd A, Hoes A. Clinical Epidemiology of heart failure. Heart 2007; 93: 1137-46;
  • Fuat A, Hungin AP, Murphy JJ. Barriers to accurate diagnosis and effective management of heart failure in primary care: qualitative study. BMJ 2003; 326: 196;
  • Loehr LR, Rosamond WD, Chang PP, et al. Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study). Am J Cardiol 2008; 101: 1016-22;
  • Gheorghiade M, Bonow RO. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation 1998; 97: 282-9;
  • He J, Ogden LG, Bazzano LA, et al. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med 2001; 161: 996-1002;
  • Agusti A, Decramer M, Celli BR, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2017 Report. © Global Initiative for Chronic Obstructive Pulmonary Disease. Available at (last accessed July 2017)
  • Ponikowski P, Voors AA, Anker SD, et al. Authors/Task Force Members, Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC), Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016; 18: 891-975;
  • Jessup M, Brozena S. Heart failure. N Engl J Med 2003; 348: 2007-18;;
  • Mant J, Doust J, Roalfe A, et al. Systematic review and individual patient data meta-analysis of diagnosis of heart failure with modelling of implications of different diagnostic strategies in primary care. Health Technol Assess 2009; 13: 1-207;
  • Williams RP, Oakeshott P. Diagnosis and management of chronic heart failure. BMJ 2014; 348: 1429;
  • Omland T, Hagve TA. Natriuretic peptides: physiologic and analytic considerations. Heart Fail Clin 2009; 5: 471-87;
  • Maisel A, Mueller C, Adams K, et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008; 10: 824-39;
  • Zaphiriou A, Robb S, Murray-Thomas T, et al. The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study. Eur J Heart Fail 2005; 7: 537-41;
  • Lainchbury JG, Troughton RW, Strangman KM, et al. NTerminal Pro-B-Type Natriuretic Peptide-Guided Treatment for Chronic Heart Failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment to Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol 2009; 55: 53-60;
  • Khunti K, Squire I, Abrams KR, et al. Accuracy of a 12-lead electrocardiogram in screening patients with suspected heart failure for open access echocardiography: a systematic review and meta-analysis. Eur J Heart Fail 2004; 6: 571-6;
  • Thomas JT, Kelly RF, Thomas SJ, et al. Utility of history, physical examination, electrocardiogram, and chest radiograph for differentiating normal from decreased systolic function in patients with heart failure. Am J Med 2002; 112: 437-45;
  • McMurray JV. Systolic Heart Failure. N Engl J Med 2010; 362: 228-38;
  • Kotecha T, Fox K. Investigating suspected heart failure. BMJ 2013; 346: 2442;
  • Bhala N, Emberson J, Mehri A, et al. Coxib and traditional NSAID Trialists’ Collaboration, Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013; 382: 769-79;
  • Ungprasert P, Patompong N, Kittanamongkolchai W. Non-steroidal anti-inflammatory drugs and risk of heart failure exacerbation: A systematic review and meta-analysis. Eur J Intern Med 2015; 26: 685-90;;
  • Faris R, Flather M, Purcell H, et al. Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials. Int J Cardiol 2002; 82: 149-58;
  • Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273: 1450-6;;
  • Granger CB, McMurray JJV, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772-6;
  • CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13;
  • Jondeau G, Neuder Y, Eicher JC, et al. B-CONVINCED: Beta-blocker CONtinuation Vs INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode. Eur Heart J 2009; 30: 2186-92;
  • Campo G, Pavasini R, Biscaglia S, et al. Overview of the pharmacological challenges facing physicians in the management of patients with concomitant cardiovascular disease and chronic obstructive pulmonary disease. Eur Heart J Cardiovasc Pharmacother 2015; 1: 205-11;
  • McMurray JJV, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993-1004;
  • Rutten FH, Clark AL, Hoes AW. How big a problem is heart failure with a normal ejection fraction? BMJ 2016; 352: i1706;
  • Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med 2009; 360: 1418-28;
  • Miró Ò, Peacock FW, McMurray JJ, et al. European Society of Cardiology - Acute Cardiovascular Care Association position paper on safe discharge of acute heart failure patients from the emergency department. Eur Heart J Acute Cardiovasc Care 2017; 6: 311-20;
  • Cleland JG, Abraham WT, Linde C, et al. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J 2013; 34: 3547-56;
  • Kajimoto K, Sato N, Takano T; investigators of the Acute Decompensated Heart Failure Syndromes (ATTEND) registry. Association of anemia and renal dysfunction with in-hospital mortality among patients hospitalized for acute heart failure syndromes with preserved or reduced ejection fraction. Eur Heart J Acute Cardiovasc Care 2016; 5: 89-99;
  • Dharmarajan K, Hsieh AF, Lin Z, et al. Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. JAMA 2013; 309: 355-63;
  • Gheorghiade M, Vaduganathan M, Fonarow GC, et al. Rehospitalization for heart failure: problems and perspectives. J Am Coll Cardiol 2013; 61: 391-403;
  • Feltner C, Jones CD, Cenè CW, et al. Transitional care interventions to prevent readmissions for persons with heart failure: a systematic review and meta-analysis. Ann Intern Med 2014; 160: 774-84;
  • Chinaglia A, Gaschino G, Asteggiano R, et al. Impact of a nurse-based heart failure management program on hospitalization rate, functional status, quality of life, and medical cost. Ital Heart J 2002; 3: 532-8
  • Lainscak M, Blue L, Clark AL, et al. Self-care management of heart failure: practical recommendations from the Patient Care Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2011; 13: 115-26;
  • Sueta CA, Rodgers JE, Chang PP, et al. Medication adherence based on part D claims for patients with heart failure after hospitalization (from the Atherosclerosis Risk in Communities Study). Am J Cardiol 2015; 116: 413-9;


Abstract: 1394 views
HTML: 1888 views
PDF: 280 views


  • There are currently no refbacks.